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significance in either case. Bowel dysfunction in ACC is 
frequently attributed to treatment-related toxicity, however our 
data support the hypothesis that dysfunction is frequently 
multifactorial, including disease, comorbidity, and psychosocial 
factors in addition to treatment factors, and that adequate 
baseline assessment of function is essential prior to CRT. 
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Purpose: Chemoradiation (CRT) followed by surgery has become 
the standard of care for the treatment of localized esophageal 
carcinoma. The rationale for this study was to examine survival 
outcomes and Quality of Life (QOL) in esophageal carcinoma 
patients treated with tri-modality therapy in a community 
cancer centre. 
Methods and Materials: Patients identified between June 2010 
and November 2015 with a diagnosis of adenocarcinoma or 
squamous cell carcinoma of the esophagus, Stage T1-4N0-3 (AJCC 
7th Ed.) and undergoing tri-modality treatment were eligible for 
this prospective cohort study. QOL (EORTC QLQ C30) and toxicity 
data (CTCAE v3.0) were collected at baseline, and four weeks, 
six months, and yearly post-completion of CRT. 
Results: Sixty patients consented to participate. Data was 
collected prospectively on 40 patients from diagnosis. Data was 
collected retrospectively for 20 patients diagnosed between 
June 2010 to February 2013 when consented at time of follow 
up, then followed prospectively thereafter. Thirty-three were 
treated with neoadjuvant CRT with 45-50 Gy in 25 fractions with 
concurrent 5FU and Cisplatin and 27 patients with 41.4 Gy in 23 
fractions, with carboplatin and paclitaxel (CROSS protocol). 
Median age was 66 years (range: 40-78) with 90% males. Median 
follow up was 13 months (range 2.3-53). Baseline QOL data was 
collected in 38 patients in the prospective group. Pathological 
complete response (pCR) rates were 38% for those receiving CRT 
with cisplatin/5FU and 22% for those treated with the CROSS 
protocol. Two-year overall survival (OS) and disease-free survival 
(DFS) was 68% and 53%, respectively with a median survival of 28 
months. No significant differences were seen in DFS or OS 
between the two treatment regimens (p = 0.95), nor were 
improved outcomes associated with achieving a pCR (p = 0.17). 
Median time to recurrence was 16 months, with locoregional 
recurrence in 17%, distant in 12% and both in 5%. No association 
was found between baseline global QOL and OS (HR = 0.9, 95% 
CI: 0.6-1.4) or DFS (HR = 0.8, 95% CI: 0.3-2.4). Additional QOL 
data will be presented. 
Conclusions: Survival outcomes in our cohort are in line with 
those reported in the literature, although pCR rates in our CROSS 
protocol group were lower compared to the CROSS study, and 
with short follow up pCR was not significantly associated with 
better survival outcomes. 
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Purpose: Radiotherapy (RT) for Hodgkin lymphoma (HL) is 
associated with late cardiac toxicity (LCT) as a potential 
complication after treatment. Risk of LCT is known to increase 
with increasing mean heart dose, however, it is unknown 
whether evaluating dose to heart substructures, such as the 
coronary arteries, will provide additional information to predict 
LCT risk. This study evaluated whether estimating dose to 
coronary arteries (CA) provided additional explanatory 
information for LCT compared to estimating whole heart dose 
alone. 
Methods and Materials: LCT status of 599 patients receiving 
mediastinal RT for HL at a tertiary cancer centre between 1988-
2003 was determined from medical records and with linkage to 
a population-based hospitalization dataset. A random sample of 
125 of these patients was selected and biomechanical 
deformable image registration was used to reconstruct 3D heart 
volumes from 2D imaging using validated methods. Historical RT 
plans were reconstructed on the 3D CT data sets and the heart 
and coronary arteries were contoured to estimate dose-volume 
variables to these structures. Principal Component analysis (PCA) 
was used to compare the proportion of variation in LCT explained 
by dose-volume variables to the whole heart versus the heart 
plus CA. The contribution (loadings) of different parameters 
(Dmean, Dmax, Dmin, V5, V10, V20, V30) to LCT occurrence was 
also evaluated. 
Results: Forty-four cases of LCT were seen, 30 of which were 
ischemic; other LCT included valvular disease, arrhythmias, 
pericardial disease, and heart failure. Median follow up was 10.4 
years (range: 0.15 – 23.8). Median Dmean to the heart, right 
coronary, left anterior descending, and circumflex arteries were 
24.6 Gy, 29.8 Gy, 17.3 Gy, and 27.3 Gy, respectively. Both the 
PCA of the heart and the heart plus CA had first components that 
explained > 50% of the variance in LCT, and there was no 
substantial improvement in explanatory power by adding CA 
doses in addition to whole heart doses to the PCA. Within 
components, no single dose-volume parameter explained a large 
proportion of LCT (i.e. loading > 0.5): in both whole heart, and 
heart plus CA models, the mean heart dose contributed most to 
explaining LCT (loading = 0.41 and 0.25, respectively).  
Conclusions: Our results indicate that estimating dose to CA will 
not add significant explanatory power to predict LCT in HL 
survivors, compared with documenting dose to the whole heart 
only. LCT risk in this setting may be mostly predicted by age, 
sex, comorbidities, and mean heart dose. However, our study 
may be underpowered to detect a small contribution from dose 
to the CA that is distinct from whole heart dose. 
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Purpose:  The management of patients with distant metastasis 
has historically been systemic therapy (ST). However, that 
paradigm is shifting to individually personalized care. 
Stereotactic body radiotherapy (SBRT) enables non-invasive 
ablation of liver metastases and its use is increasing despite the 
lack of randomized evidence. We reviewed the outcomes of liver 
metastases treated with SBRT at our institution, and evaluated 
the impact of liver SBRT on the treatment algorithm of 
metastatic patients on ST. 
Materials and Methods:  The records of 112 patients with 149 
metastatic liver lesions treated with SBRT between 2011 and 
2015 were retrospectively reviewed. Indications for treatment 
were: oligometastasis (OM) where the objective was to eradicate 
all sites of disease (≤5 sites); oligoprogression (OP) where only 
progressing lesions were treated while other sites were stable, 
and dominant area of progression (DAP) where a growing or 
symptomatic site was treated even if most or all metastatic 
deposits were progressing. Lesions were treated with either a 3, 
5 or 6 fraction regimen delivered every other day. All patients 
were evaluable for response based on contrast-enhanced CT 
obtained at minimum of 4 months after completion of SBRT. 
Local control (LC), time to liver failure (TLF), time to change ST 
